In vitro activity of trimethoprim against Borrelia burgdorferi

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 6, 1997, Pages 458-460

  Reisinger, E C ^a   Wendelin, I ^a   Gasser, R ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ARTICLE; BACTERIUM CULTURE; BORRELIA BURGDORFERI; COMPARATIVE STUDY; CONTROLLED STUDY; CULTURE MEDIUM; ESCHERICHIA COLI; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, URINARY; BORRELIA BURGDORFERI GROUP; COLONY COUNT, MICROBIAL; CULTURE MEDIA; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; SULFAMETHOXAZOLE; TRIMETHOPRIM;

EID: 0030800184     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02471911     Document Type: Article

References (14)

1. Gasser R, Dusleag J: Oral treatment of late borreliosis with roxithromycin plus co-trimoxazole. Lancet 1990, 336: 1189-1190.
2. Pedersen LM, Friis-Moller A: Late treatment of chronic Lyme arthritis. Lancet 1991, 337: 241.
3. Bowman CA: Oral treatment of late borreliosis with roxithromycin plus co-trimoxazole. Lancet 1990, 336: 1514.
4. Reisinger EC, Wendelin I, Gasser R: Inactivation of diaminopyrimidines and sulfonamides in Barbour-Stoenner-Kelly medium for isolation of Borrelia burgdorferi. European Journal of Clinical Microbiology & Infectious Diseases 1995, 14: 732-733.
5. Preac-Mursic V, Wilske B, Schierz G: European Borrelia burgdorferi isolated from humans and ticks. Culture conditions and antibiotic susceptibility. Zentralblatt für Bakteriologie und Hygiene (A) 1986, 268: 112-118.
6. Morshed MG, Konishi H, Nishimura T, Nakazawa T: Evaluation of agents for use in medium for selective isolation of Lyme disease and relapsing fever Borrelia species. European Journal of Clinical Microbiology & Infectious Diseases 1993, 12: 512-518.
7. Pollack RJ, Telford III SR, Spielman A: Standardisation of medium for culturing Lyme disease spirochetes. Journal of Clinical Microbiology 1993, 31: 1251-1255.
8. Reisinger EC, Wendelin I, Gasser R, Halwachs G, Wilders-Truschnig M, Krejs G: Antibiotics and increased temperature against Borrelia burgdorferi in vitro. Scandinavian Journal of Infectious Diseases 1996, 28: 155-157.
9. Barbour AG: Isolation and cultivation of Lyme disease spirochetes. Yale Journal of Biology and Medicine 1984, 57: 521-525.
10. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A2. NCCLS, Villanova, PA, 1990.
11. Kersten A, Poitschek C, Rauch S, Aberer E: Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi. Antimicrobial Agents and Chemotherapy 1995, 39: 1127-1133.
12. Gasser R, Wendelin I, Reisinger E, Bergloff J, Feigl B, Schafhalter I, Eber B, Grisold M, Klein W: Roxithromycin in the treatment of Lyme disease - update and perspectives. Infection 1995, 23, Supplement 1: 39-43.
13. Preac-Mursic V, Wilske B, Schierz G, Süß E, Groß B: Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. European Journal of Clinical Microbiology & Infectious Diseases 1989, 8: 651-653.
14. Hansen K, Hovmark A, Lebech AM, Lebech K, Olsson I, Sorensen L: Roxithromycin in Lyme borreliosis: discrepant results of an in-vitro and in-vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Dermatologica Venerologica 1992, 72: 297-300.